Ki-67、p53、雌激素受体、倍体和S期作为T1期淋巴结阴性乳腺癌的长期预后因素。

Ki-67, p53, ER receptors, ploidy and S phase as long-term prognostic factors in T1 node-negative breast cancer.

作者信息

Railo Mikael, Lundin Johan, Haglund Caj, von Smitten Karl, Nordling Stig

机构信息

Department of Surgery, Helsinki University Central Hospital, Helsinki, Finland.

出版信息

Tumour Biol. 2007;28(1):45-51. doi: 10.1159/000097702. Epub 2006 Dec 1.

DOI:10.1159/000097702

PMID:17143016

Abstract

BACKGROUND

The aim of the present study was to evaluate a series of biomarkers with regard to long-term prognostic value in patients with T1 (< or =2 cm) node-negative breast cancer.

METHOD

The prognostic value of Ki-67, p53, oestrogen receptor (ER) immunohistochemical labelling, flow-cytometric S phase fraction and ploidy was evaluated in 212 patients with pT1N0M0 breast cancer. The median follow-up time was 15.9 years (range 0.2-27.2 years).

RESULTS

In an analysis of breast cancer-specific survival up to 5 years, high Ki-67 (> or =10%; p = 0.002), high p53 (> or =20%; p = 0.01), negative ER (<30%; p = 0.01) as well as aneuploidy of the tumour (p = 0.02) were significant prognostic factors. When the follow-up was extended to 10 years, only Ki-67 (p = 0.03) was significantly associated with outcome and beyond 15 years none of the studied markers provided significant prognostic information when analyzed separately. There was a weak but significant difference in long-term survival when patients with a combination of high Ki-67 (> or =10%), high SPF (>3%) and high p53 (> or =20%) were compared to patients with other combinations (p = 0.03).

CONCLUSION

According to the results of our series, it seems that several prognostic markers which are associated with short-term survival (< or =5 years) in pT1N0M0 breast cancer may not be significant predictors of long-term (>15 years) breast cancer-specific survival.

摘要

背景

本研究旨在评估一系列生物标志物对T1期（≤2 cm）淋巴结阴性乳腺癌患者的长期预后价值。

方法

对212例pT1N0M0乳腺癌患者的Ki-67、p53、雌激素受体（ER）免疫组化标记、流式细胞术检测的S期细胞分数和倍体的预后价值进行评估。中位随访时间为15.9年（范围0.2 - 27.2年）。

结果

在长达5年的乳腺癌特异性生存分析中，高Ki-67（≥10%；p = 0.002）、高p53（≥20%；p = 0.01）、阴性ER（<30%；p = 0.01）以及肿瘤非整倍体（p = 0.02）是显著的预后因素。当随访延长至10年时，只有Ki-67（p = 0.03）与预后显著相关，而在15年以上时，单独分析时所研究的标志物均未提供显著的预后信息。将高Ki-67（≥10%）、高S期细胞分数（>3%）和高p53（≥20%）组合的患者与其他组合的患者相比，长期生存率存在微弱但显著的差异（p = 0.03）。